Bacterial surveillance and drug resistance analysis of ESBLs Enterobacteriaceae produced by female vaginal secretions
10.3969/j.issn.1673-4130.2019.03.022
- VernacularTitle:女性阴道分泌物产ESBLs肠杆菌科细菌监测及耐药分析
- Author:
Leiming CHEN
1
;
Yisheni CHEN
;
Wenqian SHI
;
Chunmei YING
Author Information
1. 复旦大学附属妇产科医院检验科
- Keywords:
female vaginal secretions;
ESBLs-producing strains;
drug resistance
- From:
International Journal of Laboratory Medicine
2019;40(3):348-350
- CountryChina
- Language:Chinese
-
Abstract:
Objective In order to understand the distribution and drug resistance of the extended-spectrumβ-lactamase-producing (ESBLs) Enterobacteriaceae in female vaginal secretions and to provide the basis for clinical treatment.Methods 939 strains of Enterobacteriaceae isolated from female vaginal secretions were collected from Obstetrics and Gynecology Hospital of Fudan University from January 2014 to December 2017.The strain identification and drug sensitivity test of VITECK 2 Compact-totally automatic bacterial identification analyzer were used to analyze the detection rate and drug resistance of ESBLs Enterobacteriaceae.Results 257 strains of ESBLs-producing strains were detected in 939 strains of Enterobacteriaceae with a detection rate of 27％, including 220 Escherichia coli, 34 Klebsiella pneumoniae, 2 Stink-nose Klebsiella and 1 strain of Acidogenic Klebsiella.ESBLs Escherichia coli and Klebsiella pneumoniae were all resistant to Ampicillin and Cefazolin, and to Ceftazidime, Nitrofurantoin, SMZ, Amikacin, Ciprofloxacin, Gentamicin, tobramycin, Ampicillin/Sulbactam, Ceftriaxone, Ertapenem, Piperacillin/Tazobactam, Aztreonam, Cefepime, Levofloxacin the drug resistance rates of were 36％and 44％, 2％ and 41％, 67％ and 68％, 2％ and 15％, 58％ and 38％, 51％ and65％, 14％and 26％, 65％and 76％, 99％and 97％, 0％and 29％, 0％and 3％, 50％and 65％, 26％and 18％, 57％ and 32％, but they are all sensitive to Imipenem and Cefotetan.Conclusion The inicdence of ESBLs Enterobacteriaceae in female vaginal secretions is high, and Imipenem, Cefotetan, Piperacillin/Tazobactam have high antibacterial activity, which can be used as the experience of initial treatment.
